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Purpose or Objective  
An ongoing multicenter observational study, registered at 
ClinicalTrials.gov, is assessing the intestinal, hematologic 
and urinary toxicity from whole-pelvis radiotherapy 
(WPRT) in the radical, adjuvant or salvage RT treatment 
of prostate cancer. The Inflammatory Bowel Disease 
Questionnaire (IBDQ) is used to evaluate radiation-
induced Intestinal Toxicity (IT): it explores 10 Bowel 
symptoms and their possible detrimental effect on 
Emotional, Social and Systemic Domains. The responses 
are scored from 7 (best function) to 1 (worst). This 
analysis focuses on acute IT. 
Material and Methods  
Patients (pts) treated with conventional fractionation or 
moderate hypofractionation are included. Static-field 
IMRT (SS-IMRT), Tomotherapy (TOMO) and VMAT are 
allowed. WPRT is at the discretion of the referring 
radiation oncologist. The IBDQ was completed at 
baseline, at RT mid-point and end.  For this analysis, 
focused on the first 303 pts with complete IBDQ at 
baseline and radiotherapy mid-point and end, a 
worsening in single bowel symptoms ≥3 points was set as 
endpoint for IT definition. This worsening corresponds to 
50% of the total possible score, which could be of interest 
from a clinical perspective. The largest IBDQ worsening 
between baseline and RT mid-point or end was 
considered. Associations between IT and 
patient/treatment related factors were evaluated 
through logistic regression (LR).  Further analyses were 
performed to identify the symptoms more closely 
associated with detriment in Social, Emotional and 
Systemic domains. 
Results  
303 pts having the complete set of IBDQs were 
considered. Eight per cent were treated by means of SS-
IMRT, 42% of TOMO and 50% of VMAT. The median EQDQ2 
(a/b=3Gy) dose to the prostate/prostatic bed was 72.58 
Gy, that to pelvic lymph-nodes/pelvic lymph-nodal area 
was 50 Gy. Rates of significant worsening for each 
symptom are reported in Table 1a.  SS-IMRT was 
associated with an increased risk (OR≈0.3, p=0.01÷0.05, 
as compared to VMAT/TOMO) of abdominal pain, cramps, 
rectal bleeding and nausea/feeling sick. In addition, the 
volume of lymph-nodal PTV (median 1020cc, range 338-
1606) was associated with an increased risk of abdominal 
pain and cramps (OR≈1.2 for 100cc, p=0.01÷0.05). The 
results of multivariable analysis pertaining to QoL 





Even in the era of modern IMRT, WPRT-induced IT is non-
negligible, leading to moderate/severe symptom rates 
ranging from 7 to 50%. Extended WPRT fields are related 
to increased abdominal pain/cramps, while RT technique 
impacts abdominal pain, cramps, rectal bleeding and 
nausea, as a possible consequence of the reduced ability 
of SS-IMRT in sparing bowel volumes receiving 40-50 Gy.  
Social domain is highly influenced by frequent bowel 
movements and loose stool, while rectal bleeding impacts 
Emotional wellbeing.  
 
PO-0821  Radiation-induced late rectal toxicity for 
IMPT vs VMAT in patients with localized prostate 
cancer 
C. Hammer1, C.L. Brouwer1, P. Klinker1, S. Both1, S. 
Aluwini1, J.A. Langendijk1 
1University Medical Center Groningen, Radiation 
Oncology, Groningen, The Netherlands 
 
Purpose or Objective  
Over the years, multiple NTCP models have been 
published regarding radiation-induced late rectal 
toxicity, but only a few included other toxicities besides 
rectal bleeding. Peeters et al.1 published NTCP models 
for high stool frequency, fecal incontinence and rectal 
bleeding. 
Recent improved planning techniques for photon therapy 
(VMAT dual-arc) as well as proton therapy (CTV-based 
robust IMPT) could further reduce late rectal toxicity. 
The purpose of this in silico planning study was to asses 
predicted radiation-induced late rectal toxicity after 
treatment of localized prostate cancer for these modern 
photon and proton techniques. 
Material and Methods  
For this study, 20 planning-CT scans were used of 
patients treated at our department in 2015-2017  for 
localized prostate cancer. The dose prescription included 
77 Gy(RBE) to the prostate (and part of/whole vesicles), 
and 70 Gy(RBE) to (part of) the vesicles (depending on 
tumor stage), where RBE=1.1. The CTV-PTV margin for 
the photon plans was 5 mm laterally and 6 mm in other 
directions. Proton therapy plans were robustly optimized 
using 5 mm setup laterally and 6 mm in other directions 
and 3% range uncertainty. Plans were evaluated for 
robustness using shifts in 26 directions (photons and 
protons) and range uncertainties +/- 3% (only protons). 
Plans were optimized until ≥ 98% of the CTV was covered 
with ≥ 95% of the dose in the voxel wise minimum 
scenario. Late rectal toxicity grade ≥ 2 was assessed using 
NTCP models of Peeters et al.1 for rectal bleeding, stool 
frequency and fecal incontinence. 
Results  
Overall, most proton plans resulted in a slightl y lower 
predicted incidence of late rectal toxicity than thephoton 
plans (Figure 1). Most absolute differences were seen for 
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fecal incontinence in patients with a history of abdominal 
surgery, i.e., 7.5% (mean; photons) and 5.6% (mean; 
protons).  
For high stool frequency the differences were smaller, 
but in most patients in favor of proton therapy. Rectal 
bleeding was 0% in both groups. In the Netherlands, one 
of the indications to receive proton therapy for the 
treatment of localized prostate cancer is a reduction ≥ 
10% for grade 2 toxicity. Using these models, only 
maximal 1 of 20 patients would be selected for proton 
therapy, which was a patient with endpoint fecal 
incontinence (with history of abdominal surgery). 
  




CTV-based robust IMPT resulted in slightly lower NTCP’s 
for late rectal toxicity and thus have a potential benefit 
relative to VMAT. Application of the Dutch guideline and 
the use of above mentioned NTCP models and endpoints 
would lead to a relative small selection of approximately 
0-5% of the patients with localized prostate cancer for 
proton therapy.  
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Purpose or Objective  
Purpose: to evaluate biochemical control, toxicity and 
patient function after prostate cancer treatment with 
moderate hypofractionated and dose-escalated image-
guided volumetric modulated arc therapy (VMAT) for 
localized prostate cancer in an observational study. 
Material and Methods  
Material and methods: From 2010 to 2017, men with 
localized prostate cancer (from low to high-risk) who 
received VMAT to a dose of 66 Gy in 22 fractions of 3 Gy, 
and had over 2 years follow-up, were eligible. After the 
treatment, patients were followed every three months 
the first two years and then every six months. Endpoints 
included acute toxicity at the end of treatment and late 
gastrointestinal (GI) and genitourinary (GU) toxicity using 
the Radiation Therapy Oncology Group (RTOG) scoring, 
biochemical control and patient reported outcomes using 
the Expanded Prostate Cancer Index (EPIC-26). 
Results  
Results: One hundred and sixteen men became eligible. 
With a median follow-up of 40 months, acute GI and GU 
Grade2 toxicity were 26% and 12%, respectively. 
Cumulative late Grade2 GI and GU toxicity was 1% and 4% 
respectively. No Grade3 acute or late toxicity were 
reported. Biochemical control was 97%. Ninety patients 
(78%) completed the EPIC-26 form. Patient-reported 
outcomes showed no urinary and bowel general problems 
in 76% and 91%, respectively. The proportion of patients 
reporting moderate urinary problems was 2,2% (2 
patients). No moderate or severe bowel problems were 
reported. 
Conclusion  
Conclusion: Dose escalation to 66 Gy with moderate hypo 
fractionated VMAT is associated with favourable late 
toxicity, biochemical control and good patient reported 
outcomes with over two years follow-up. 
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Purpose or Objective  
Variation in radiotherapy target volume and OAR 
delineation is one of the largest contributing factors to 
the global uncertainty in treatment delivery. Further, it 
is acknowledged that it is also an obstacle to effective 
clinical trials in advanced treatment techniques if not 
accounted for in the experimental design. However, 
manual expert review of delineation for all patients 
enrolled prior to treatment is logistically arduous and 
expensive. We propose a scalable cloud based automated 
solution for trial specific review of delineation accuracy, 
The Radiotherapy Atlas Contouring (TRAC) tool. TRAC has 
the added benefit of enabling rapid clinical translation of 
study findings into regular practice. 
 
Material and Methods  
Retrospective data from the prostate SBRT trial 
PROMETHEUS (ACTRN12615000223538) was utilised for 
this study. Multi-atlas generation consisted of MRI data 
from 10 patients, five observers, three anatomical 
structures and a rectal stabilisation device. The rectal 
stabilisation devices approved for use in the study 
included the RectaFixTM and SpaceOAR® hydrogel. 
Tolerance for delineation acceptability was based on 
observer variation in multi-atlas generation. Where 
necessary the manual expert reviewer delineated a 
corrected contour for comparison. Thus, for each patient 
there were a number of structures deemed correct and 
incorrect by manual review for testing. A random forest 
classifier was trained using a number of contour features 
(DSC, Components, Volume, Elongation, Perimeter, 
